Encouraging early Covid-19 vaccine data

Preliminary data suggest that CoronaVac, an experimental Covid-19 vaccine from Beijing-based Sinovac Biotech, might indeed protect people from the novel coronavirus. Preliminary results from a 600-patient, placebo-controlled Phase 2 study found that “above 90%” of people tested two weeks after receiving the vaccine developed neutralizing antibodies, STAT’s Adam Feuerstein writes.

Sinovac still hasn’t provided much detail about CoronaVac’s safety and efficacy — though plans to do so in the “near future.” There are more than two dozen research efforts underway to develop a vaccine against the novel coronavirus.